326030 — SK Biopharmaceuticals Share News
0.000.00%
Last trade - 00:00- KR₩6tn
- KR₩5tn
- KR₩707bn
US FDA pauses new enrollment in Biohaven's epilepsy drug trials (updated)
US FDA pauses new enrollment in Biohaven's epilepsy drug trials
Biohaven jumps on SK Biopharma epilepsy licensing deal worth up to $795 million
U.S. STOCKS ON THE MOVE-Meta, Kohl's, J.M. Smucker
U.S. STOCKS ON THE MOVE-Semtech, Donaldson, Meta
Biohaven jumps on SK Biopharma epilepsy licensing deal worth up to $795 million
Biohaven licenses epilepsy drug to South Korea's SK Biopharmaceuticals for up to $795 million
Brief: Sk Biopharmaceuticals Co Q2 Operating. Profit 97 Billion Won, Up 57% Y/Y
Brief: Sk Biopharmaceuticals Co Wins 81 Billion Won Order
Insilico Medicine hits 3-week high on SK Biopharmaceuticals tie-up
Signs Joint Rd Partnership Agreement With Insilico Medicine
Brief: Insilico Medicine Cayman TopCo Says Co & SK Biopharmaceuticals Enter AI-Powered RD Collab Worth Up To $2.5 Bln
Brief: SK Life Science Announces FDA Acceptance For Review Of New Drug Application For Cenobamate Oral Suspension
Announces Pharmaceutical Supply Contract
Ir Meeting Scheduled For May 20-21, 2026
Brief: SK Biopharmaceuticals Co Q1 Preliminary Operating Profit 89.8 Billion Won Up 249.7% Y/Y
Brief: Sk Biopharmaceuticals Co Wins 843 Billion Won Contract
Shares of Asian drugmakers drop after Trump threatens tariffs (updated)
Shares of South Korea’s drugmakers drop after Trump unveils tariffs